M
Marc Carrier
Researcher at Ottawa Hospital Research Institute
Publications - 396
Citations - 17092
Marc Carrier is an academic researcher from Ottawa Hospital Research Institute. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 58, co-authored 325 publications receiving 12428 citations. Previous affiliations of Marc Carrier include Ottawa Hospital & University of Ottawa.
Papers
More filters
Journal ArticleDOI
Residual pulmonary embolism as a predictor for recurrence after a first unprovoked episode: Results from the REVERSE cohort study
Tony Wan,Marc A. Rodger,Wanzhen Zeng,Philippe Robin,Marc Philip Righini,Michael J. Kovacs,Melanie Tan,Marc Carrier,Susan R. Kahn,Philip S. Wells,David Anderson,Isabelle Chagnon,Susan Solymoss,Mark Crowther,Richard H. White,Linda M. Vickars,Sadri Bazarjani,Grégoire Le Gal,Grégoire Le Gal +18 more
TL;DR: Residual pulmonary embolism assessed by pulmonary vascular obstruction on baseline ventilation-perfusion performed after 5-7months of oral anticoagulant therapy for the first episode of unprovoked pulmonary emblism was associated with a statistically significant higher risk of subsequent recurrent venous thromboembolism.
Journal ArticleDOI
Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: Rational and design of the AVERT trial
TL;DR: AVERT will randomize 574 ambulatory cancer patients receiving chemotherapy who are at high-risk for VTE to Apixaban 2.5 mg BID versus placebo, and hopefully offer evidence regarding the benefit of apixaban in ambulatory patients at high risk for V TE receiving chemotherapy.
Journal ArticleDOI
Anticoagulant medication adherence for cancer-associated thrombosis: A comparison of LMWH to DOACs.
Jordan K. Schaefer,Mengbing Li,Zhenke Wu,Tanima Basu,Michael P. Dorsch,Geoffrey D. Barnes,Marc Carrier,Jennifer J. Griggs,Suman L. Sood +8 more
TL;DR: Medication adherence was high (~95%) and was similar with LMWH compared to DOACs and the proportion of days covered (PDC) was close to zero.
Journal ArticleDOI
Long-term risk of postthrombotic syndrome after symptomatic distal deep vein thrombosis: The CACTUS-PTS study
Jean-Philippe Galanaud,Jean-Philippe Galanaud,Marc Philip Righini,Lorris Le Collen,Aymeric Douillard,Helia Robert-Ebadi,D. Pontal,David R. Morrison,M.-T. Barrellier,Antoine Diard,Hervé Guenneguez,D. Brisot,Pascale Faisse,Sandrine Accassat,Myriam Martin,Aurélien Delluc,Susan Solymoss,Jeannine Kassis,Marc Carrier,Isabelle Quéré,Susan R. Kahn +20 more
TL;DR: After a proximal lower limb deep vein thrombosis (DVT; involving popliteal veins or above), up to 40% of patients develop postthrombotic syndrome (PTS) as assessed by the Villalta scale (VS).
Journal ArticleDOI
Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores
TL;DR: An overview of the available clinical prediction scores for major bleeding in patients with VTE is provided, highlighting the methodological shortcomings with their derivation and validation, summarize their performance, and provide considerations for bleeding risk assessment in clinical practice.